LB Pharmaceuticals Inc (LBRX)
NASDAQ: LBRX · Real-Time Price · USD
15.04
-0.97 (-6.06%)
At close: Oct 8, 2025, 4:00 PM EDT
15.04
0.00 (0.00%)
After-hours: Oct 8, 2025, 4:10 PM EDT

Company Description

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.

Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation.

The company was incorporated in 2015 and is headquartered in New York, New York.

LB Pharmaceuticals Inc
CountryUnited States
Founded2015
IPO DateSep 11, 2025
IndustryBiotechnology
SectorHealthcare
Employees16
CEOHeather Turner

Contact Details

Address:
One Pennsylvania Plaza, Suite 1025
New York, New York 10119
United States
Phone212 605 0300
Websitelbpharma.us

Stock Details

Ticker SymbolLBRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code0001691082
SIC Code2834

Latest SEC Filings

DateTypeTitle
Sep 25, 2025SCHEDULE 13DFiling
Sep 19, 2025SCHEDULE 13GFiling
Sep 19, 2025SCHEDULE 13DFiling
Sep 18, 2025SCHEDULE 13GFiling
Sep 18, 2025SCHEDULE 13GFiling
Sep 12, 20258-KCurrent Report
Sep 12, 2025424B4Prospectus
Sep 11, 2025S-8Securities to be offered to employees in employee benefit plans
Sep 10, 2025EFFECTNotice of Effectiveness
Sep 10, 2025S-1MEFRegistration adding securities to prior Form S-1 registration